PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Science. Author manuscript; available in PMC 2009 February 1.
Published in final edited form as:
PMCID: PMC2490797
NIHMSID: NIHMS56966

Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target

Abstract

Cyclin D1 (CyD1) is a pivotal cell cycle-regulatory molecule and a well-studied therapeutic target for cancer. Although CyD1 is also strongly up-regulated at sites of inflammation, its exact roles in this context remain uncharacterized. To address this question, we developed a strategy for selectively silencing CyD1 in leukocytes in vivo. Targeted stabilized nanoparticles (tsNPs) were loaded with CyD1-small interfering RNA (siRNA). Antibodies to β7 integrin (β7 I) were then used to target specific leukocyte subsets involved in gut inflammation. Systemic application of β7 I-tsNPs silenced CyD1 in leukocytes and reversed experimentally induced colitis in mice by suppressing leukocyte proliferation and T helper cell 1 cytokine expression. This study reveals CyD1 to be a potential anti-inflammatory target, and suggests that the application of similar modes of targeting by siRNA may be feasible in other therapeutic settings.

RNA interference (RNAi) has emerged as a powerful strategy for suppressing gene expression, offering the potential to dramatically accelerate in vivo drug target validation, as well as the promise to create novel therapeutic approaches if it can be effectively applied in vivo (1). Cyclin D1 (CyD1) is a key cell cycle-regulating molecule that governs the proliferation of normal and malignant cells (2, 3). In inflammatory bowel diseases, colon-expressed CyD1 is aberrantly up-regulated in both epithelial and immune cells (4, 5). Although CyD1 has also been implicated in promoting epithelial colorectal dysplasia and carcinogenesis, it is not clear whether leukocyte-expressed CyD1 contributes directly to the pathogenesis of inflammation and whether it might serve as a therapeutic target.

To address these questions, we used RNAi silencing of CyD1 in an experimental model of intestinal inflammation. A major limitation to the use of RNAi in vivo is the effective delivery of siRNAs to the target cells (6, 7). RNAi in leukocytes, a prime target for anti-inflammatory therapeutics, has remained particularly challenging, as these cells are difficult to transduce by conventional transfection methods and are often disseminated throughout the body, thus requiring systemic delivery approaches (8). One possibility is to use integrins, which are an important family of cell-surface adhesion molecules, as targets for siRNA delivery (8). Specifically, we have shown that antibody-protamine fusion proteins directed to the lymphocyte function-associated antigen-1 (LFA-1) integrin selectively delivered siRNAs to leukocytes, both in vitro and in vivo (8). However, whether an integrin-directed siRNA delivery approach can induce sufficiently robust silencing in vivo remains to be seen.

Building on the premise of integrin-targeted siRNA delivery, we developed liposome-based, β7 integrin-targeted, stabilized nanoparticles (β7 I-tsNPs) that entrap siRNAs (Fig. 1) (9). We began with nanometer-scale (~80 nm) liposomes, formed from neutral phospholipids to circumvent the potential toxicity common to cationic lipids and polymers used for systemic siRNA delivery (10). Hyaluronan was then attached to the outer surface of the liposomes, through covalent linkage to dipalmitoylphosphatidylethanolamine (DPPE), thereby stabilizing the particles both during subsequent siRNA entrapment (Fig. 1) and during systemic circulation in vivo (11). The resulting stabilized nano-particles (sNPs) were successfully equipped with a targeting capacity by covalently attaching a monoclonal antibody against the integrins to hyaluronan (fig. S1). The antibody FIB504 (12) was selected to direct particles to β7 integrins, which are highly expressed in gut mononuclear leukocytes (13).

Fig. 1
The processes involved in generating I-tsNPs. Multilamellar vesicle (MLV) [prepared as described in (9)] is extruded to form a unilamellar vesicle (ULV) with a diameter of ~100 nm. Hyaluronan is covalently attached to DPPE in the ULV. A monoclonal ...

We condensed siRNAs with protamine, a positively charged protein that has been used to enhance delivery of nucleic acids [e.g., DNA (14)and siRNA (15)]. β7 I-tsNPs were loaded with siRNA cargo by rehydrating lyophilized particles in the presence of condensed siRNAs (9), thereby achieving ~80% entrapment efficacy while maintaining the nanodimensions of the particles (tables S1 and S2). β7 I-tsNPs showed a measurable increase in their capacity to entrap siRNAs such that I-tsNPs carried ~4000 siRNA molecules per particle (~100 siRNA molecules per targeting antibody molecule) (table S1), as compared to an integrin-targeted single-chain antibody protamine fusion protein, which carried five siRNA molecules per fusion protein (8). The presence of hyaluronan was critical to maintaining the structural integrity of I-tsNPs during the cycle of lyophilization and rehydration (table S3 and fig. S2).

Cy3-siRNA encapsulated within β7 I-tsNPs was efficiently bound and delivered to wild-type (WT) but not to β7 integrin knockout (KO) splenocytes (Fig. 2A). Upon cell binding, β7 I-tsNPs readily internalized and released Cy3-siRNA to the cytoplasm of both WT splenocytes (Fig. 2B) and the TK-1 lymphocyte cell line (fig. S3) but not that of β7 integrin KO cells (Fig. 2B). Neither naked siRNA nor isotype control immunoglobulin G (IgG)-attached stabilized nanoparticles (IgG-sNPs) delivered Cy3-siRNA above background levels (Fig. 2, A and B). Using siRNA to Ku70, a ubiquitously expressed nuclear protein and reference target, we showed that Ku70-siRNA delivered by β7 I-tsNPs induced potent gene silencing in splenocytes, whereas naked or IgG-sNP-formulated Ku70-siRNA did not (Fig. 2C) (additional results in figs. S4 to S7).

Fig. 2
β7 I-tsNP delivers siRNAs in leukocytes in a β7-specific manner. (A) Cy3-siRNA delivery via β7 I-tsNP to WT, but not to β7 knockout (KO), splenocytes as revealed by flow cytometry. (B) Confocal microscopy with differential ...

To investigate the ability of β7 I-tsNPs to silence genes in vivo, we administered Ku70-siRNAs (2.5 mg per kilogram of body weight) entrapped in β7 I-tsNPs by intravenous injection into mice and tested Ku70 expression in mononuclear leukocytes isolated from the gut and spleen after 72 hours (Fig. 2D) (9). Ku70-siRNAs delivered by β7 I-tsNPs potently suppressed Ku70 expression in cells from the gut (including lamina propria and intraepithelial lymphocyte compartments) and spleen. No silencing was observed in cells from identically treated β7 integrin KO mice, confirming the specificity to the β7 integrin-expressing cells. Furthermore, naked siRNA as well as siRNA delivered in IgG-sNPs failed to induce detectable silencing in WT or KO mice.

We subsequently examined the biodistribution of 3H-hexadecylcholesterol-labeled nanoparticles intravenously injected into healthy or diseased mice suffering from dextran sodium sulfate (DSS)-induced colitis (Fig. 2E) (9). IgG-sNPs showed very little distribution to the gut regardless of the presence of colitis. By contrast, a substantial portion (~10%) of β7 I-tsNPs spread to the gut in healthy mice. The biodistribution of β7 I-tsNPs to the gut selectively increased ~3.5-fold in the presence of colitis.

Using β7 I-tsNPs, we next studied the effects of silencing by CyD1-siRNA (9). Treatment with β7 I-tsNP-entrapped CyD1-siRNA reduced CyD1 mRNA expression in stimulated splenocytes, leading to potent suppression of proliferation (Fig. 3A). β7 I-tsNPs-entrapped CyD1-siRNA (2.5 mg/kg) was then administered intravenously. Three days later, splenic and gut mononuclear leukocytes from mice treated with β7 I-tsNP-entrapped CyD1-siRNA showed significantly decreased CyD1 mRNA and reduced proliferation (Fig. 3A).

Fig. 3
Silencing of CyD1 by siRNA delivery with β7 I-tsNPs and its effects on cytokine expression. (A) Silencing of CyD1 [measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR)] and its effects on proliferation (measured by ...

Although CyD1-knockdown blocked agonist-enhanced expression of the T helper cell 1 (TH1) cytokines interferon-γ (IFN-γ), interleukin-2 (IL-2), IL-12, and tumor necrosis factor-α (TNF-α), it did not alter the expression of the TH2 cytokines IL-4 and IL-10 in either CD3/CD28- or phorbol 12-myristate 13-acetate (PMA)/ionomycin-stimulated splenocytes (Fig. 3B and fig. S8) or in PMA/ionomycin-stimulated TK-1 cells (fig. S9). The preferential inhibition of TH1 cytokines was not observed with the CyD2- or CyD3-knockdown (fig. S9). To investigate whether the CyD1-knockdown suppressed TH1 cytokine expression independently of its inhibitory effects on the cell cycle, we treated TK-1 cells with aphidicolin to arrest the cell cycle independently of the CyD1 status (Fig. 3C) (9). In aphidicolin-treated cells, PMA/ionomycin up-regulated CyD1 as well as TH1 and TH2 cytokines. CyD1-knockdown selectively suppressed TH1 cytokine mRNA expression in aphidicolin-treated and PMA/ionomycin-activated cells (Fig. 3C). This cell cycle-independent suppression of TH1 cytokines was also seen with the individual applications of four different CyD1-siRNAs that targeted non-overlapping sequences in CyD1 mRNA (Fig. 3D), thereby ruling out the possibility that the blockade of TH1 cytokines was due to an off-target effect. Thus, CyD1-knockdown could preferentially suppress pro-inflammatory TH1 cytokine expression independently of any changes in the cell cycle.

We next studied CyD1-knockdown with β7 I-tsNPs in vivo in DSS-induced colitis (9). Mice were intravenously injected with CyD1-siRNA (2.5 mg/kg) entrapped in β7 I-tsNPs or IgG-sNPs at days 0, 2, 4, and 6. β7 I-tsNP-delivered CyD1-siRNA potently reduced CyD1 mRNA to a level comparable with that of the uninflamed gut (Fig. 4D). CyD1-knockdown concomitantly suppressed mRNA expression of TNF-α and IL-12, but not of IL-10 (Fig. 4D). Notably, β7 I-tsNP-delivered CyD1-siRNA led to a drastic reduction in intestinal tissue damage, to a potent suppression of leukocyte infiltration into the colon, and to a reversal in body weight loss and hematocrit reduction (Fig. 4, A to C, and fig. S10). The gut tissue of CyD1-siRNA/β7 I-tsNP-treated animals exhibited normal numbers of mononuclear cells (Fig. 4C), suggesting that CyD1-knockdown does not induce pathologic cell death in the gut. CyD1-siRNAs entrapped in IgG-sNPs did not induce silencing in the gut, failing to alter cytokine expression in the gut or to reverse manifestations of colitis (Fig. 4, A to C) (additional results in figs. S11 and S12).

Fig. 4
Cyclin-D1-siRNA delivered by β7 I-tsNP alleviated intestinal inflammation in DSS-induced colitis. Mice were intravenously administered CyD1- or luciferase (Luci)-siRNAs (2.5 mg/kg) entrapped in either β7 I-tsNPs or IgG-sNPs, or naked CyD1-siRNA ...

The anti-inflammatory effects of CyD1-knockdown in colitis are likely to be mediated both by suppressing the aberrant proliferation of mucosal mononuclear leukocytes and by reducing the expression of TNF-α and IL-12, two pro-inflammatory TH1 cytokines that are critical to the pathogenesis of colitis. The TH2 cytokine IL-10 has been shown to suppress inflammation in colitis (16). Thus, its transformation from a relatively TH1-dominant to a more TH2-dominant phenotype appears to represent a critical and unexpected component of the potent colitis inhibition resulting from CyD1-knockdown. An important future goal will be to elucidate the molecular mechanisms underlying the effects of CyD1-knockdown, both on the induction of TH2 polarization and on the specific type(s) of leukocytes responsible for reversal of colitis.

Entrapment of condensed siRNA inside these nanoparticles, in tandem with the targeting of the leukocyte β7 integrin, which readily internalizes bound particles, enabled both highly efficient intracellular delivery and gene silencing in vivo. An effective in vivo siRNA dose of 2.5 mg/kg is one of the lowest doses reported to date for systemically targeted siRNA-delivery applications (17-22). Compared to other strategies, tsNPs offer the combined benefits of low off-target/toxicity with high cargo capacity (~4000 siRNA molecules per NP). Encapsulation of siRNA within the tsNPs seems to both protect siRNA from degradation (fig. S5) and prevent triggering of unwanted interferon responses (fig. S6). Antibodies coated on the outer surface of the NPs provided selective cellular targeting, while cell surface integrins proved to be effective antibody targets for both delivery and uptake of tsNPs. Thus, the I-tsNP approach may have broad applications not only for in vivo drug target validation, but also for potential therapies that are not limited to leukocytes or inflammatory settings.

Supplementary Material

Acknowledgments

We thank J. Lieberman for critically reading manuscript and discussion; R. Margalit, R. S. Langer, and P. Sicinski for discussions; and Y. Imai, A. Zur, P. Sage, and R. Yoo for technical assistance. D.P. is supported by the Dorot Foundation and Pfizer Inc. Y.M. is supported by the Uehara Memorial Foundation. This work was supported by the Arthritis Foundation (C.V.C.) and NIH grants HL048675 and AI63421 (M.S.).

Footnotes

Supporting Online Material

www.sciencemag.org/cgi/content/full/319/5863/627/DC1

Materials and Methods

Figs. S1 to S12

Tables S1 to S3

References

References and Notes

1. Iorns E, Lord CJ, Turner N, Ashworth A. Nat. Rev. Drug Discov. 2007;6:556. [PubMed]
2. Stacey DW. Curr. Opin. Cell Biol. 2003;15:158. [PubMed]
3. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Endocrinology. 2004;145:5439. [PubMed]
4. Yang R, Bie W, Haegebarth A, Tyner AL. Cell Cycle. 2006;5:180. [PubMed]
5. van Dekken H, et al. Acta Histochem. 2007;109:266. [PubMed]
6. Behlke MA. Mol. Ther. 2006;13:644. [PubMed]
7. Dykxhoorn DM, Lieberman J. Annu. Rev. Biomed. Eng. 2006;8:377. [PubMed]
8. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Proc. Natl. Acad. Sci. U.S.A. 2007;104:4095. [PubMed]
9. Materials and methods are available as supporting material on Science Online
10. Dass CR. J. Mol. Med. 2004;82:579. [PubMed]
11. Peer D, Florentin A, Margalit R. Biochim. Biophys. Acta. 2003;1612:76. [PubMed]
12. Andrew DP, et al. J. Immunol. 1994;153:3847. [PubMed]
13. Shaw SK, Brenner MB. Semin. Immunol. 1995;7:335. [PubMed]
14. Sorgi FL, Bhattacharya S, Huang L. Gene Ther. 1997;4:961. [PubMed]
15. Li SD, Huang L. Mol. Pharm. 2006;3:579. [PubMed]
16. Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJ. Dig. Dis. Sci. 2004;49:1327. [PubMed]
17. Soutschek J, et al. Nature. 2004;432:173. [PubMed]
18. Morrissey DV, et al. Nat. Biotechnol. 2005;23:1002. [PubMed]
19. Schiffelers RM, et al. Nucleic Acids Res. 2004;32:e149. [PMC free article] [PubMed]
20. Song E, et al. Nat. Biotechnol. 2005;23:709. [PubMed]
21. Takeshita F, et al. Proc. Natl. Acad. Sci. U.S.A. 2005;102:12177. [PubMed]
22. Heidel JD, et al. Proc. Natl. Acad. Sci. U.S.A. 2007;104:5715. [PubMed]